A Phase 2a Safety and Efficacy Open-Label Study of Tulisokibart (MK-7240/PRA023) in Participants With Moderately to Severely Active Crohn's Disease (MK-7240-006)

BIOLOGICAL: Tulisokibart
DIAGNOSTIC_TEST: Companion Diagnostic (CDx)

PHASE2

Phase

COMPLETED

Status

Enrollment

INDUSTRY

Sponsor class

Conditions

Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)